Vision to become the primary alternative to heart transplants with the implementation of our Total Artificial Heart
A medical device company developing the world’s most advanced total artificial heart. The company aim to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, composed of the implantable bioprosthesis and its portable external power supply system to which it is connected, it intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.
Aeson is composed of 3 parts:
- implanted prosthesis
- external equipment
- hospital care console
Visit website: https://www.carmatsa.com/
People at Carmat
French artificial heart maker CARMAT receives a financial boost
Longevity Technology - 16-Oct-2023
Aims to reach an annual production capacity of 500 artificial heartsRead more...
CARMAT raised €40.5 million - set to resume the artificial heart production
Longevity Technology - 21-Apr-2022
Aeson could prolong lives of patients awaiting a human heart transplantRead more...
Clinical experience in artificial heart with autoregulation of blood flow
pharmaphorum - 15-Jul-2021
New heart replacement therapy for patients with end-stage biventricular failureRead more...